title: Enhanced tumor targeting of cRGD peptide-conjugated albumin nanoparticles in the BxPC-3 cell line.
abstract: The emerging albumin nanoparticle brings new hope for the delivery of antitumor drugs. However, a lack of robust tumor targeting greatly limits its application. In this paper, cyclic arginine-glycine-aspartic-conjugated, gemcitabine-loaded human serum albumin nanoparticles (cRGD-Gem-HSA-NPs) were successfully prepared, characterized, and tested in vitro in the BxPC-3 cell line. Initially, 4-N-myristoyl-gemcitabine (Gem-C14) was formed by conjugating myristoyl to the 4-amino group of gemcitabine. Then, cRGD-HSA was synthesized using sulfosuccinimidyl-(4-N-maleimidomethyl)cyclohexane-1-carboxylate (Sulfo-SMCC) cross-linkers. Finally, cRGD-Gem-HSA-NPs were formulated based on the nanoparticle albumin-bound (nab) technology. The resulting NPs were characterized for particle size, zeta potential, morphology, encapsulation efficiency, and drug loading efficiency. In vitro cellular uptake and inhibition studies were conducted to compare Gem-HSA-NPs and cRGD-Gem-HSA-NPs in a human pancreatic cancer cell line (BxPC-3). The cRGD-Gem-HSA-NPs exhibited an average particle size of 160 ± 23 nm. The encapsulation rate and drug loading rate were approximately 83 ± 5.6% and 11 ± 4.2%, respectively. In vitro, the cRGD-anchored NPs exhibited a significantly greater affinity for the BxPC-3 cells compared to non-targeted NPs and free drug. The cRGD-Gem-HSA-NPs also showed the strongest inhibitory effect in the BxPC-3 cells among all the analyzed groups. The improved efficacy of cRGD-Gem-HSA-NPs in the BxPC-3 cell line warrants further in vivo investigations.
authors: Pancreatic Surgery Department, Huashan Hospital, Fudan University. Shanghai 200040,China.
authors: Xinzhe
authors: X
authors: Yu
authors: School of Pharmacy, The Second Military Medical University, Shanghai 200433, P.R.China.
authors: Yunlong
authors: Y
authors: Song
authors: Pancreatic Surgery Department, Huashan Hospital, Fudan University. Shanghai 200040,China.
authors: Yang
authors: Y
authors: Di
authors: Pancreatic Surgery Department, Huashan Hospital, Fudan University. Shanghai 200040,China.
authors: Hang
authors: H
authors: He
authors: Pancreatic Surgery Department, Huashan Hospital, Fudan University. Shanghai 200040,China.
authors: Deliang
authors: D
authors: Fu
authors: Pancreatic Surgery Department, Huashan Hospital, Fudan University. Shanghai 200040,China.
authors: Chen
authors: C
authors: Jin
mesh_terms: D000418:Albumins / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology; D045744:Cell Line, Tumor; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology; D016503:Drug Delivery Systems / Q000379:methods*; D006801:Humans; D053758:Nanoparticles / Q000737:chemistry / Q000627:therapeutic use; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D010456:Peptides, Cyclic / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology; D000093542:Gemcitabine
chemical_list: D000418:Albumins; D010456:Peptides, Cyclic; C507169:cyclic arginine-glycine-aspartic acid peptide; D003841:Deoxycytidine; D000093542:Gemcitabine